NASDAQ:OBSV ObsEva (OBSV) Stock Forecast, Price & News $0.06 -0.01 (-14.29%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$0.06▼$0.0850-Day Range$0.04▼$0.1052-Week Range$0.08▼$2.14Volume6,980 shsAverage Volume8.94 million shsMarket Capitalization$4.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About ObsEva (NASDAQ:OBSV) StockObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Read More OBSV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OBSV Stock News HeadlinesSeptember 17, 2023 | americanbankingnews.comObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.comJune 18, 2023 | fool.comObsEva (NASDAQ: OBSV)September 22, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.March 31, 2023 | finance.yahoo.comObsEva Files Year End 2022 Financial StatementsMarch 15, 2023 | finance.yahoo.comObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023March 13, 2023 | markets.businessinsider.comObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim ChairmanMarch 13, 2023 | finance.yahoo.comObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in SwitzerlandMarch 3, 2023 | benzinga.comWhy Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day SessionSeptember 22, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. March 3, 2023 | investorplace.comWhy Is ObsEva (OBSV) Stock Up 93% Today?February 24, 2023 | investorplace.comWhy ObsEva (OBSV) Stock Is Down 36% TodayFebruary 24, 2023 | finance.yahoo.comObsEva Announces Strategic Reorganization to Consolidate Operations in SwitzerlandJanuary 12, 2023 | uk.finance.yahoo.comObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request FilingDecember 19, 2022 | finance.yahoo.comObsEva Announces Dismissal of Moratorium ProceedingsDecember 14, 2022 | finance.yahoo.comObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request FilingDecember 1, 2022 | finance.yahoo.comObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue EstimatesDecember 1, 2022 | finance.yahoo.comObsEva Announces Third Quarter 2022 Financial Results and Provides a Business UpdateOctober 27, 2022 | finance.yahoo.comObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium ProceedingsOctober 16, 2022 | finance.yahoo.comObsEva SA (OBSV)October 14, 2022 | markets.businessinsider.comObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of NolasibanOctober 13, 2022 | finance.yahoo.comObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo FinanceOctober 13, 2022 | marketscreener.comObsEva Says Partner Yuyuan Bioscience Obtained Regulatory Nod for Nolasiban Drug Trial in China - Marketscreener.comOctober 13, 2022 | benzinga.comObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China - ObsE - BenzingaOctober 13, 2022 | marketscreener.comObsEva's Chinese Partner Wins Regulatory Nod To Launch Early-stage Trial Of Clinical Pregnancy Drug - Marketscreener.comOctober 13, 2022 | globenewswire.comObsEva Announces IND Approval for Yuyuan Bioscience's Phase - GlobeNewswireOctober 13, 2022 | finance.yahoo.comObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in ChinaOctober 6, 2022 | reuters.comOBSV.PH - Obseva SA | Stock Price & Latest News | ReutersSee More Headlines Receive OBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter. Email Address OBSV Company Calendar Last Earnings11/04/2021Today9/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OBSV CUSIPN/A CIK1685316 Webwww.obseva.com Phone(122) 552-3840FaxN/AEmployees48Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-416.36% Return on Assets-92.01% Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.61 Sales & Book Value Annual Sales$20.11 million Price / Sales0.23 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book0.15Miscellaneous Outstanding Shares77,971,000Free Float66,743,000Market Cap$4.68 million OptionableNot Optionable Beta0.68 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesWilliam M. BrownChief Executive & Financial OfficerElke BestelVP, Head-Drug Safety & PharmacovigilanceKatja BuhrerChief Strategy OfficerKey CompetitorsCyclacel PharmaceuticalsNASDAQ:CYCCLixte BiotechnologyNASDAQ:LIXTPanbela TherapeuticsNASDAQ:PBLAKiora PharmaceuticalsNASDAQ:KPRXHillstream BioPharmaNASDAQ:HILSView All CompetitorsInstitutional OwnershipSimplex Trading LLCSold 200 shares on 8/4/2023Ownership: 0.000%View All Institutional Transactions OBSV Stock - Frequently Asked Questions How have OBSV shares performed in 2023? ObsEva's stock was trading at $0.1450 on January 1st, 2023. Since then, OBSV shares have decreased by 58.6% and is now trading at $0.06. View the best growth stocks for 2023 here. How were ObsEva's earnings last quarter? ObsEva SA (NASDAQ:OBSV) issued its quarterly earnings results on Thursday, November, 4th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.23. What other stocks do shareholders of ObsEva own? Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA). When did ObsEva IPO? (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. What is ObsEva's stock symbol? ObsEva trades on the NASDAQ under the ticker symbol "OBSV." Who are ObsEva's major shareholders? ObsEva's stock is owned by many different institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%). How do I buy shares of ObsEva? Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ObsEva's stock price today? One share of OBSV stock can currently be purchased for approximately $0.06. How much money does ObsEva make? ObsEva (NASDAQ:OBSV) has a market capitalization of $4.68 million and generates $20.11 million in revenue each year. The company earns $-58,380,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. How can I contact ObsEva? ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The official website for the company is www.obseva.com. The company can be reached via phone at (122) 552-3840 or via email at ir@obseva.ch. This page (NASDAQ:OBSV) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.